GLP-1 Rebound Weight Gain: Clinical Evidence and Management
Comments Off on GLP-1 Rebound Weight Gain: Clinical Evidence and Management
May 13, 2026
GLP-1 rebound effects cause weight regain after stopping therapy, reflecting metabolic setpoint return. Understanding these effects is crucial for managing long-term weight. This article reviews clinical evidence and management approaches for GLP-1…
Louisiana Bill Expands Medicaid Coverage for GLP-1 Receptor Agonists
Comments Off on Louisiana Bill Expands Medicaid Coverage for GLP-1 Receptor Agonists
May 5, 2026
Medicaid coverage GLP-1 receptor agonist expansion in Louisiana aims to improve access to obesity treatment for vulnerable populations. Senate Bill 433 proposes coverage for semaglutide and tirzepatide under Medicaid. This legislative change addresses…